Immune Design Corp (NASDAQ:IMDZ)‘s stock had its “buy” rating reissued by equities researchers at Jefferies Group LLC in a research note issued on Friday. They currently have a $18.00 target price on the biotechnology company’s stock, up from their prior target price of $16.00. Jefferies Group LLC’s target price indicates a potential upside of 146.58% from the stock’s current price.

Separately, Zacks Investment Research raised shares of Immune Design Corp from a “sell” rating to a “hold” rating in a research note on Thursday.

Immune Design Corp (NASDAQ:IMDZ) opened at 7.30 on Friday. The stock’s market capitalization is $186.67 million. Immune Design Corp has a 12 month low of $4.50 and a 12 month high of $14.21. The company has a 50-day moving average of $6.28 and a 200 day moving average of $6.28.

Immune Design Corp (NASDAQ:IMDZ) last posted its earnings results on Tuesday, March 7th. The biotechnology company reported ($0.57) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.57). The company had revenue of $2.06 million during the quarter, compared to analysts’ expectations of $1.34 million. Immune Design Corp had a negative net margin of 415.05% and a negative return on equity of 50.92%. On average, equities research analysts anticipate that Immune Design Corp will post ($2.33) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/05/20/jefferies-group-llc-reaffirms-buy-rating-for-immune-design-corp-imdz.html.

A number of institutional investors have recently bought and sold shares of IMDZ. BVF Inc. IL bought a new position in Immune Design Corp during the third quarter valued at $9,096,000. Victory Capital Management Inc. boosted its position in Immune Design Corp by 11.6% in the first quarter. Victory Capital Management Inc. now owns 1,937,554 shares of the biotechnology company’s stock valued at $13,175,000 after buying an additional 202,149 shares during the last quarter. Baker BROS. Advisors LP bought a new position in Immune Design Corp during the third quarter valued at $1,129,000. Oxford Asset Management bought a new position in Immune Design Corp during the fourth quarter valued at $565,000. Finally, Perceptive Advisors LLC bought a new position in Immune Design Corp during the fourth quarter valued at $428,000. 53.07% of the stock is owned by institutional investors.

About Immune Design Corp

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

12 Month Chart for NASDAQ:IMDZ

Receive News & Ratings for Immune Design Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp and related companies with MarketBeat.com's FREE daily email newsletter.